NU Skin Enterprises Inc. (NYSE: NUS) has recently been highlighted by Stonegate Capital Partners for its outstanding quarterly performance and strategic growth initiatives. The company reported revenue, adjusted Net Income, and adjusted EPS of $386.1M, $21.1M, and $0.43, respectively, with revenue reaching the high end of its guidance range. A standout segment, Rhyz Manufacturing, achieved a 17% year-over-year revenue growth, while EPS significantly exceeded guidance.
The company's gross margin for the quarter was 68.8%, showing a quarter-over-quarter expansion of 106 bps from 1Q25. This improvement is credited to NU Skin's dedication to revenue growth and operational optimization, resulting in a 103.5% year-over-year growth in adjusted Net Income. Stonegate Capital Partners remains optimistic about NU Skin's potential for continued margin expansion and its strong positioning for the upcoming quarter.
NU Skin is currently advancing two key strategic initiatives aimed at driving growth. The first involves expanding into India, with pre-opening activities planned for 4Q25 and a full launch expected by mid-2026. The second initiative is the introduction of the Prysm iO wellness device, an AI-powered tool designed to offer personalized product recommendations, which is expected to significantly enhance the company's product offerings and energize its brand representatives and sales leaders.
Despite experiencing a year-over-year decrease in sales leaders, paid affiliates, and customers, NU Skin reported a remarkable 107% revenue growth in Latin America, thanks to its scalable digital-first model. The company's financial health is robust, with $264.2M in cash on hand and achieving a net cash position ahead of schedule, providing the necessary flexibility to execute its strategic initiatives effectively.
Following a strong performance in the quarter, NU Skin has adjusted its FY25 revenue guidance to $1.48B to $1.55B and raised its adjusted EPS guidance to $1.15 to $1.35. Stonegate Capital Partners has valued NU Skin at a forward Price to Adj. EPS of 5.2x, suggesting a valuation range of $10.95 to $17.21 per share. For more information on NU Skin's performance and strategic initiatives, visit https://www.nuskin.com.
